Cathie Wood’s ARK Invest ETFs (exchange-traded funds) executed a series of trades on Tuesday, August 26, 2025, according to the funds’ daily disclosures. The trades reflect ARK’s continued confidence in the biotechnology sector, increasing its stake in gene-editing players, namely CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA). Meanwhile, ARK trimmed its holdings in TV streaming giant Roku (ROKU) and online sports betting operator DraftKings (DKNG).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wood Expands Biotech Exposure with CRISPR, Intellia Buys
The largest trade of the day came in CRISPR, with the ARK Innovation ETF (ARKK) purchasing 165,874 shares valued at roughly $8.98 million. This follows Monday’s buy of 188,879 shares for $10.26 million, underscoring Wood’s growing confidence in the gene-editing company’s long-term potential.
ARKK also boosted its stake in Intellia, adding 191,705 shares worth about $2.18 million. The company has seen repeated purchases in recent days. Just yesterday, Wood picked up 359,000 shares valued at $3.78 million, signaling a clear push into the gene-editing space.
ARK Trims Stakes in Roku and DraftKings
On the selling side, Wood has steadily reduced ARK’s position in Roku over the past several days. On Tuesday, the fund sold shares worth $6.61 million, likely taking advantage of Roku’s recent rally. Roku stock has gained 33% over the past three months.
ARK also cut its stake in DraftKings, unloading about $6.04 million worth of shares. The stock has climbed 34% in the past three months. The continued sales in Roku and DraftKings may signal a shift in strategy or a reaction to market trends.
On a smaller scale, the ARK Next Generation Internet ETF (ARKW) reduced positions in Coinbase (COIN) and Shopify (SHOP), with sales valued at approximately $597,312 and $588,680, respectively. These moves extend a recent pattern of trimming exposure to high-growth tech names.
Let’s take a brief look at how all these stocks perform on TipRanks’ Stock Comparison Tool:
